SeekingAlpha · Sep 29, 2026
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Palvella Therapeutics advances QTORIN rapamycin for microcystic lymphatic malformations with strong Phase 3 data. Read more on PVLA stock here.
PV
NASDAQ · PVLA
Palvella Therapeutics, Inc.
Healthcare · Biotechnology
$132.16
Down-$4.16 (-3.15%)
Updated Oct 7, 2026, 1:03 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.15B
- P/E ratio
- -28.63
- Dividend yield
- 0.00%
- 52-week range
- $100.00 – $161.38
- Volume
- 142.88K
- Avg. volume
- 211.26K
Price performance · PVLA
PVLA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
PVLA closed at $132.16 after 20 trading sessions, down 13.21% for the selected period.
- Last close
- $132.16
- Period change
- -13.21%
- Period low
- $132.16
- Period high
- $158.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $132.50 | $133.265 | $129.51 | $132.16 | 142.88K |
| Oct 2, 2026 | $135.15 | $137.0364 | $127.26 | $132.47 | 348.13K |
| Oct 1, 2026 | $135.57 | $139.23 | $131.65 | $132.73 | 343.37K |
| Sep 30, 2026 | $141.14 | $142.9603 | $137.30 | $137.93 | 262.31K |
| Sep 29, 2026 | $140.20 | $141.54 | $136.18 | $139.00 | 215.01K |
| Sep 28, 2026 | $138.13 | $143.55 | $137.425 | $139.83 | 188.62K |
| Sep 25, 2026 | $147.02 | $147.44 | $137.86 | $138.16 | 193.34K |
| Sep 24, 2026 | $148.05 | $149.11 | $143.08 | $146.07 | 185.06K |
| Sep 23, 2026 | $157.62 | $157.62 | $147.4301 | $149.56 | 180.6K |
| Sep 22, 2026 | $155.08 | $160.84 | $153.64 | $158.13 | 276.63K |
| Sep 21, 2026 | $152.40 | $155.11 | $151.31 | $153.41 | 123.59K |
| Sep 18, 2026 | $154.72 | $154.72 | $149.2025 | $150.56 | 646.46K |
| Sep 17, 2026 | $154.78 | $156.785 | $151.55 | $154.32 | 157.92K |
| Sep 16, 2026 | $152.54 | $155.18 | $150.755 | $151.43 | 201.97K |
| Sep 15, 2026 | $152.72 | $155.63 | $148.145 | $151.22 | 215.63K |
| Sep 14, 2026 | $150.14 | $153.405 | $150.14 | $151.69 | 223.05K |
| Sep 11, 2026 | $152.75 | $154.30 | $149.9825 | $150.13 | 163.37K |
| Sep 10, 2026 | $148.43 | $151.365 | $147.10 | $150.39 | 266.08K |
| Sep 9, 2026 | $147.26 | $155.00 | $145.91 | $151.34 | 149.39K |
| Sep 8, 2026 | $153.42 | $157.93 | $151.58 | $152.28 | 165.03K |
Latest PVLA news
The latest Smart Investors Daily articles mentioning PVLA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PVLA research
Overview
Company profile and research snapshot.
Company profile
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $141.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | Chardan Capital | Buy | — |
| May 21, 2026 | Stephens & Co. | Overweight | — |
| May 21, 2026 | Chardan Capital | Buy | — |
| May 12, 2026 | Stephens & Co. | Overweight | — |
| Mar 31, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 28, 2026
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S. WAYNE, Pa., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a cli
Benzinga · Sep 28, 2026
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
The award follows FDA review of Palvella’s annual performance progress report, which included results from the Phase 3 SELVA trial. In February 2026, Palvella announced positive topline results from the Phase 3 SELVA
Yahoo · Sep 9, 2026
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamyci
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
